Table 1.
The general information and laboratory data of the new diagnosed metabolic syndrome patients at the baseline and 12 weeks after the therapy.
| Before medication | After medication | P value | |
|---|---|---|---|
| Participants (M/F) | 37 (17/20) | 37 (17/20) | |
| Age (years) | 41.1 ± 7.3 | 41.1 ± 7.3 | |
| Body mass index (kg/m2) | 31.5 ± 3.6 | 27.4 ± 2.4 | <0.01 |
| Waist circumference (cm) | 97.3 ± 10.5 | 92.1 ± 9.10 | 0.04 |
| Systolic pressure (mmHg) | 146.1 ± 14.9 | 134.0 ± 13.3 | 0.32 |
| Diastolic pressure (mmHg) | 95.5 ± 8.7 | 88.5 ± 10.3 | 0.24 |
| Total cholesterol (mM) | 6.69 ± 1.04 | 5.74 ± 0.84 | 0.03 |
| High-density lipoprotein cholesterol (mM) | 1.09 ± 0.36 | 0.92 ± 0.36 | 0.06 |
| Low-density lipoprotein cholesterol (mM) | 3.68 ± 0.85 | 2.86 ± 0.57 | 0.03 |
| Triglyceride (mM) | 3.03 ± 2.05 | 1.86 ± 0.90 | <0.01 |
| Fasting plasma glucose (mM) | 7.37 ± 0.72 | 6.13 ± 0.85 | 0.03 |
| HbA1c (%) | 7.10 ± 0.64 | 6.04 ± 0.62 | 0.02 |
| Leptin (ug/L) | 8.01 (2.04~15.17) | 5.12 (1.88~12.89) | 0.04 |
| Adiponectin (mg/L) | 8.42 (4.75~14.81) | 10.02 (5.13~15.59) | 0.14 |
| Leptin/adiponectin | 0.76 (0.29~2.85) | 0.58 (0.14~1.22) | 0.02 |
| Fasting insulin (mIU/L) | 16.90 (11.6~20.1) | 12.50 (9.7~14.8) | 0.04 |
| HOMA-IR | 5.46 (3.62~6.69) | 3.25 (2.50~4.58) | 0.03 |
| Glutamic-pyruvic transaminase (U/L) | 37.28 ± 4.12 | 39.89 ± 7.08 | 0.62 |
| γ-Glutamyl transpeptidase (U/L) | 48.71 ± 8.12 | 41.79 ± 7.11 | 0.74 |
| Creatinine (mM) | 87.45 ± 4.71 | 89.11 ± 8.07 | 0.77 |
t-test of paired measurement data comparisons between two comparing lines before and after medication. Data of nonnormal distribution were described using the median (M) and quartile (Q1~Q4).